AGTX Agentix Corp.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1603345 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY44.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-10,542.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets290,269.6%
Debt / equity—
Current ratio0.00x
Interest coverage-3.57x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-9,875.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $125,079 | $180,987 |
| SG&A expense | $68,072 | $69,898 |
| Operating income | -$445,187 | -$513,251 |
| Interest expense | $80,106 | $42,669 |
| Pretax income | -$485,636 | -$567,048 |
| Income tax | $0 | $0 |
| Net income | -$485,636 | -$567,048 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 40.07M | 40.07M |
| Balance sheet | ||
| Cash & equivalents | $771 | $4,477 |
| Current assets | $771 | $100,274 |
| Total assets | $771 | $100,274 |
| Current liabilities | $3.60M | $3.20M |
| Total liabilities | $3.60M | $3.20M |
| Shareholders' equity | -$3.60M | -$3.10M |
| Shares outstanding | 40.07M | 40.07M |
| Cash flow statement | ||
| Operating cash flow | -$108,529 | -$125,078 |
| Investing cash flow | $0 | $0 |
| Financing cash flow | $110,450 | $100,000 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.